Vicarious Surgical

Vicarious Surgical, Inc. engages in advancing the field of surgical robotics. Through the use of surgical robotics, the company aims to improve patients lives, surgeons abilities, and expand global access to high-quality care. The company was founded by Adam Sachs and Sammy Khalifa on May 6, 2020 and is headquartered in Waltham, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Vicarious Surgical reports progress in procedures and system development

Vicarious Surgical demonstrated strong performance in Q4 2022 with successful procedures and system advancements.
While facing financial challenges, the company's strategic strengths and opportunities position them for future growth.
Maintaining a balance between innovation, cost management, and regulatory milestones will be key for Vicarious Surgical.

Vicarious Surgical reports Q1 progress amidst regulatory discussions and innovation

Vicarious Surgical's Q1 2023 performance reflects progress in refining their robotic system and managing expenses, with a strong cash position and ongoing FDA discussions.
The company's strengths lie in innovation, regulatory focus, and strategic spending, positioning them well for future growth and expansion into new indications.
Challenges include high operating expenses and regulatory uncertainties, while opportunities exist in enhancing their technology and capitalizing on market potential through disciplined investments.

Vicarious Surgical reports Q2 loss, eyes FDA milestones for growth

Vicarious Surgical's Q2 performance reflects a focus on innovation, regulatory compliance, and strategic leadership.
The company's strong cash position, upcoming milestones, and product development efforts signal growth potential.
Challenges in managing expenses, regulatory hurdles, and market competition require careful navigation and strategic planning.
Opportunities lie in expanding partnerships, FDA approvals, and leveraging the demand for minimally invasive surgical solutions.

Vicarious Surgical reports improved finances but faces delays in flagship program

Vicarious Surgical navigated challenges with financial improvements but faces delays in their flagship program. Despite setbacks, the company remains committed to revolutionizing robotic surgery and enhancing capital efficiency.

Vicarious Surgical reports progress in product development and funding

Vicarious Surgical navigated challenges in 2023, strengthened its product offering, and secured funding for future growth. The company's financial position is stable, with a focus on achieving milestones in 2024. Leveraging partnerships and regulatory clarity present growth opportunities.

Vicarious Surgical reports strong Q1 performance and eyes global expansion

Vicarious Surgical's Q1 2024 performance reflects financial improvements and technological advancements, positioning the company for future growth.
While facing challenges in system integration and regulatory processes, the company's strengths in technology innovation and leadership provide a strong foundation for success.
Opportunities in international expansion, strategic partnerships, and regulatory advancements present avenues for Vicarious Surgical to capitalize on its unique market position and drive long-term value.

Vicarious Surgical reports Q2 progress amidst financial challenges

Vicarious Surgical's Q2 2024 performance showed progress in system integration and partnerships, but also highlighted financial challenges.
The company's strong cash position and focus on upcoming milestones position it well for future growth opportunities.
Analyst questions underscore the need for Vicarious Surgical to address financial concerns and execute on its strategic initiatives effectively.

Vicarious Surgical reports improved financials and progresses on robotic platform

Vicarious Surgical's Q3 2024 performance showed financial improvements and progress in developing its single-port platform for robotic surgery. While challenges and uncertainties exist, the company's focus on cost management and regulatory readiness bode well for future growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vicarious Surgical, Inc. a blank check company, which engages in effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It also designs surgical robotics. The company was founded by Adam Sachs, Sammy Khalifa, and Barry Greene on May 1, 2014 and is headquartered in Waltham, MA.

Key Partnership Providing Further Support Toward Vicarious System Finalization, Regulatory Submission, and Commercialization Goals

Vicarious Surgical Announces Memorandum of Understanding Agreement with Pittsburgh CREATES to Advance System Design

Vicarious Surgical to Report Third Quarter 2022 Financial Results on November 7, 2022

Vicarious Surgical Announces Upcoming Beta 2 Demonstration Day

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced the company will present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Management is scheduled to present on Wednesday, August 31, 2022 at 11:30 am ET. Interested part

Vicarious Surgical to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

Vicarious Surgical Inc. (NYSE:RBOT ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Kaitlyn Brosco - Director, Investor Relations Adam Sachs - Chief Executive Officer Bill Kelly - Chief Financial Officer Conference Call Participants Matt Miksic - Barclays Operator Good afternoon and welcome to Vicarious Surgical's Second Quarter 2022 Earnings Conference Call. My name is Brica, and I will be your operator for today's call.

Vicarious Surgical Inc. (RBOT) CEO Adam Sachs on Q2 2022 Results - Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended June 30, 2022. Management will host a corresponding conference call at 4:30 p.m. ET today, August 8, 2022. “We are excited to step closer toward our regulatory and commercial go

Vicarious Surgical Reports Second Quarter 2022 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced the company will participate in the Canaccord Genuity 42nd Annual Growth Conference. Management is scheduled to present on Wednesday, August 10 at 9:30 a.m. ET. A live webcast of the presentation will be accessible to the

Vicarious Surgical to Present at the Canaccord Genuity 42nd Annual Growth Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the second quarter 2022 after the market closes on Monday, August 8, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the

Vicarious Surgical to Report Second Quarter 2022 Financial Results on August 8, 2022

Blade Air Mobility

Borr Drilling Ltd

Callon Petroleum

EVgo

Power REIT

U.S. Silica Holdings

Although equities just finished one of the worst first-half performances ever, it also opened doors to the best bargain stocks to buy. The post 7 Best Bargain Stocks to Buy in July 2022 appeared first on InvestorPlace.

7 Best Bargain Stocks to Buy in July 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced it is set to join the broad-market Russell 3000® Index as well as the Russell 2000® and Russell Microcap® Indexes at the conclusion of the 2022 Russell indexes annual reconstitution, according to a preliminary list of add

Vicarious Surgical Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced the company will participate in a virtual fireside chat at the Cowen 7th Annual FutureHealth Conference. Management is scheduled to present on Wednesday, June 22 at 10:50 a.m. ET. A live webcast of the presentation will b

Vicarious Surgical to Present at the Cowen 7th Annual FutureHealth Conference

Vicarious Surgical Inc. (NYSE:RBOT ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Marissa Bych - Gilmartin Group Adam Sachs - Co Founder & Chief Executive Officer Bill Kelly - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Operator Good afternoon, and welcome to Vicarious Surgical's First Quarter 2022 Earnings Conference Call. My name is Amber, and I will be your moderator for today's call.

Vicarious Surgical Inc. (RBOT) CEO Adam Sachs on Q1 2022 Results - Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended March 31, 2022. Management will host a corresponding conference call at 4:30 p.m. ET today, May 9, 2022. “We have made measurable progress against our developmental and organiza

Vicarious Surgical Reports First Quarter 2022 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter 2022 after the market closes on Monday, May 9, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the con

Vicarious Surgical to Report First Quarter 2022 Financial Results on May 9, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical, Inc. (“Vicarious Surgical” or the “Company”), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced qualification of its cleanroom for manufacturing of the Vicarious System. The cleanroom substantially augments the company's existing capabilities by providing an environmentally controlled and easily expandable space for precision assembly. Through rigorous testing, the

Vicarious Surgical Announces Cleanroom Qualification for Manufacturing of the Vicarious System

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as the cost and efficiency of surgical procedures, today announced the appointment of John Mazzola as vice president of operations. In this new role, Mazzola will lead the strategic manufacturing plans for the Vicarious system as the company progresses development. Mazzola has more than 3

Vicarious Surgical Appoints John Mazzola as Vice President of Operations

Piper Sandler has downgraded Vicarious Surgical Inc (NASDAQ: RBOT) to Neutral from Overweight with a price target of $7, down from $16, below expected Q4 results.  A majority of the earnings call focused on the Company's regulatory update.

Analysts Move To Sidelines On Vicarious Surgical After Regulatory Update

Vicarious Surgical Inc. (RBOT) CEO Adam Sachs on Q4 2021 Results - Earnings Call Transcript

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced its preliminary unaudited fourth quarter and full year 2021 financial results. “2021 was an incredible year at Vicarious Surgical. I want to congratulate our team and thank our investors, advisors, and partners for su

Vicarious Surgical Reports Fourth Quarter and Full Year 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced that the company will be participating in the following virtual investor conferences. Cowen 42nd Annual Healthcare Conference Presentation on Tuesday, March 8, at 9:10 a.m. ET Oppenheimer 32nd Annual Healthcare Conference

Vicarious to Participate in Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced it will report financial results for the fourth quarter 2021 after the market closes on Thursday, March 3, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors

Vicarious Surgical to Report Fourth Quarter 2021 Financial Results on March 3, 2022

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced the company will participate in a fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Management is scheduled to present on February 16 at 4:00 p.m. Eastern Time. To listen t

Vicarious Surgical to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Berkshire Grey

Intuitive Surgical

Luminar Technologies

Ouster, Inc

Titan Medical Inc

Trimble

Velodyne Lidar

Zebra Technologies

December 2021 saw investments in robotics of roughly USD1.2bn. The lion's share of the funding in went to autonomous driving companies.

Robotics Investments In December 2021

WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical is proud to announce it has been honored with three awards from Built In's 2022 Best Places To Work Awards. Specifically, Vicarious Surgical earned a place in the following three categories in Boston: Best Places to Work, Best Midsize Companies to Work for, and Best Paying Companies. The annual awards program includes companies of all sizes, from startups to large enterprises, and honors companies in the eight largest tech markets across the U

Vicarious Surgical Receives Three Built In Boston's 2022 Best Places to Work Awards

BOSTON--(BUSINESS WIRE)--Vicarious Surgical (NYSE: RBOT, RBOT WS) announces it has won the MedTech Powerhouse Company of the Year Award at the 2021 NEVY Awards, hosted by the New England Venture Capital Association (NEVCA). The theme this year highlighted the “heroes” of New England's innovation ecosystem—the entrepreneurs and investors committed to leveraging science and technology for a better tomorrow. “It is an honor to be named MedTech Powerhouse Company of the Year by the NEVYs,” said Ada

News for Vicarious Surgical Stock (RBOT)